In the last trading session, 2.14 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) were traded, and its beta was 1.79. Most recently the company’s share price was $51.19, and it changed around -$0.98 or -1.88% from the last close, which brings the market valuation of the company to $4.42B. CRSP currently trades at a discount to its 52-week high of $63.68, offering almost -24.4% off that amount. The share price’s 52-week low was $30.04, which indicates that the current value has risen by an impressive 41.32% since then. We note from CRISPR Therapeutics AG’s average daily trading volume that its 10-day average is 4.07 million shares, with the 3-month average coming to 2.63 million.
CRISPR Therapeutics AG stock received a consensus recommendation rating of Buy, based on a mean score of 1.93. If we narrow it down even further, the data shows that 1 out of 28 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 10 recommended CRSP as a Hold, whereas 12 deemed it a Buy, and 0 rated it as Underweight.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP has showed a red trend with a performance of -1.88% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 53.08 on recent trading dayincreased the stock’s daily price by 3.56%. The company’s shares are currently down -3.62% year-to-date, but still up 7.79% over the last five days. On the other hand, CRISPR Therapeutics AG (NASDAQ:CRSP) is 34.53% up in the 30-day period. We can see from the shorts that 21.41 million shares have been sold at a short interest cover period of 9.74 day(s).
The consensus price target as assigned by Wall Street analysts is $65, which translates to bulls needing to increase their stock price by 21.25% from its current value. Analyst projections state that CRSP is forecast to be at a low of $65 and a high of $65.
CRISPR Therapeutics AG earnings are expected to increase by -25.48% in 2025, but the outlook is positive 5.55% per year for the next five years.
CRSP Dividends
CRISPR Therapeutics AG’s next quarterly earnings report is expected to be released on 2025-May-06.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.69% of CRISPR Therapeutics AG shares, and 76.46% of them are in the hands of institutional investors. The stock currently has a share float of 77.78%. CRISPR Therapeutics AG stock is held by 529.0 institutions, with CAPITAL INTERNATIONAL INVESTORS being the largest institutional investor. By 2024-06-30, it held 9.2619% of the shares, which is about 7.87 million shares worth $424.8 million.
ARK INVESTMENT MANAGEMENT LLC, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
